Organogenesis Holdings Inc
NASDAQ:ORGO
Intrinsic Value
Organogenesis Holdings, Inc. is a regenerative medical company. [ Read More ]
The intrinsic value of one
ORGO
stock under the Base Case scenario is
3.58
USD.
Compared to the current market price of 3.03 USD,
Organogenesis Holdings Inc
is
Undervalued by 15%.
Organogenesis Holdings Inc's market capitalization is 397.9m USD.
ORGO stock price is 3.03 USD.
ORGO stock price (3.03 USD) is 15% less than its Intrinsic Value (3.58 USD).
ORGO has upside potential of 63% compared to the average analyst price target.
Open Wall St Estimates
ORGO has positive Net Income for the last twelve months.
ORGO has positive Operating Income for the last twelve months.
ORGO's Revenue has dropped by 4% over the past 12 months.
ORGO has positive Free Cash Flow for the last twelve months.
ORGO's Revenue is forecast to grow at a rate of 7% per year over the next 3 years.
ORGO's Revenue has been growing by 9% per year for the last 3 years.
ORGO's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 2%.
ORGO's ROE (Return on Equity) for the past 12 months is very low and is equal to 2%.
ORGO's Altman Z-Score is equal to 2.79.
ORGO has positive three-year average ROIC (Return on Invested Capital): 21%. The company is efficient at using invested capital to generate operating income.
ORGO's ROE (Return on Equity) has significantly decreased in the last 3 years from 44% to 2%.
ORGO's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 30% to 2%.
ORGO has negative Net Debt. This means that the company has more cash and short-term investments (104m USD) than debt (63m USD).
ORGO has very high three-year average ROE (Return on Equity): 27%. The company is very efficient at transforming stockholders' equity into net income.
ORGO's long-term assets (460m USD) exceed its long-term liabilties (181m USD).
ORGO has positive Gross Profit for the last twelve months.
ORGO's short-term assets (225m USD) exceed its short-term liabilties (81m USD).
ORGO's D/E (Debt to Equity) is very low and is equal to 0.22.
ORGO generates enough operating income (13m USD) to cover interest payments on its debt (5m USD).
Valuation Backtest
Organogenesis Holdings Inc
Run backtest to discover the historical profit from buying and selling
ORGO
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Organogenesis Holdings Inc
Balance Sheet Decomposition
Organogenesis Holdings Inc
| Current Assets | 225m |
| Cash & Short-Term Investments | 103.8m |
| Receivables | 82m |
| Other Current Assets | 39.2m |
| Non-Current Assets | 235m |
| PP&E | 156.3m |
| Intangibles | 44.6m |
| Other Non-Current Assets | 34m |
| Current Liabilities | 80.5m |
| Accounts Payable | 30.7m |
| Accrued Liabilities | 43.2m |
| Other Current Liabilities | 6.6m |
| Non-Current Liabilities | 100.9m |
| Long-Term Debt | 62.6m |
| Other Non-Current Liabilities | 38.2m |
Earnings Waterfall
Organogenesis Holdings Inc
|
Revenue
|
433.1m
USD
|
|
Cost of Revenue
|
-106.5m
USD
|
|
Gross Profit
|
326.7m
USD
|
|
Operating Expenses
|
-314.1m
USD
|
|
Operating Income
|
12.5m
USD
|
|
Other Expenses
|
-7.6m
USD
|
|
Net Income
|
4.9m
USD
|
Free Cash Flow Analysis
Organogenesis Holdings Inc
ORGO Profitability Score
Profitability Due Diligence
Organogenesis Holdings Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
Score
Organogenesis Holdings Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
ORGO Solvency Score
Solvency Due Diligence
Organogenesis Holdings Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Organogenesis Holdings Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ORGO Price Targets Summary
Organogenesis Holdings Inc
According to Wall Street analysts, the average 1-year price target for
ORGO
is 4.93 USD
with a low forecast of 3.54 USD and a high forecast of 6.3 USD.
Ownership
ORGO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ORGO Price
Organogenesis Holdings Inc
| Average Annual Return | -4.57% |
| Standard Deviation of Annual Returns | 59.98% |
| Max Drawdown | -92% |
| Market Capitalization | 397.9m USD |
| Shares Outstanding | 131 963 000 |
| Percentage of Shares Shorted | 27.32% |
Company Profile
Organogenesis Holdings Inc
Country
Industry
Market Cap
Dividend Yield
Description
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.
Contact
IPO
Employees
Officers
The intrinsic value of one
ORGO
stock under the Base Case scenario is
3.58
USD.
Compared to the current market price of 3.03 USD,
Organogenesis Holdings Inc
is
Undervalued by 15%.
You don't have any saved screeners yet
